Company name: Brains Bioceutical
Description: Manufacturer of cannabinoid active pharmaceutical created to source naturally-active pharmaceutical ingredients. The company has a full line of products including CBD capsules and tinctures along with specific, non-medical grade needs as well, enabling clients to get access to quality GMP-certified naturally-sourced active pharmaceutical ingredients.
Industry: Healthcare | Group: | Code:
State: British Columbia
Start up capital raised (USD Million): 30.00
Business status: Clinical Trials – Phase 3
Ownership: Privately Held (backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: The company raised $30 million of venture funding from undisclosed investors on December 19, 2019. The funds will be used to expand Brains’ existing UK CBD API production growing its current annual capacity from 864,000g to 6,912,000g per annum, a near seven-fold increase.
Number of active investors:
Profile last updated: 20-Dec-2019
Last known valuation:
Last known valuation date: